Prothrombinkomplexkonzentrate (Faktor II-VII-IX-X-Komplex)

E. Lechler

doi:10.1055/s-0038-1656574

Hämostaseologie, Table of Contents

Hamostaseologie 1982; 02(03): 116-127
DOI: 10.1055/s-0038-1656574

Originalarbeiten

Schattauer GmbH

Prothrombinkomplexkonzentrate (Faktor II-VII-IX-X-Komplex)

Eigenscaften und klinische Anwendung

E. Lechler

¹Aus der Medizinischen Universitätsklinik Köln (Direktor: Prof. Dr. R. Gross)

› Author Affiliations

Abstract

Full Text

References

LITERATUR
1 Abildgaard U. A review of antithrombin III. In Collen D., Wiman B., Ver-straete M. (Hrsg.): The physiological inhibitors of blood coagulation and fibrinolysis Elsevier/North Holland; Amsterdam: 19 1979
2 Abildgaard C. F., Britton M., Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J. Pediatr. 1976; 88: 200.
3 Aggeler P. M., Hoag M. S., Kropat-kin M. L., Kaplan S.S. Problems involved in the measurement of factor IX: physiological and clinical implications. In Brinkhous K. M. (Hrsg.): The hemophilias The University of North Carolina Press; Chapel Hill: 1964: 131
4 Aggeler P. M., White S. G., Glen-dening M. D., Page E. W., Leake T. B., Bates G. Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc. Soc. Biol. Med. 1952; 79: 692.
5 Agrawal B. L., Zelkowitz L., Hletko P. Acute myocardial infarction in a young hemophilic patient during therapy with factor IX concentrate and epsilon aminocaproic acid. J. Pediatr. 1981; 98: 931.
6 Allain J. P. Étude de l'activité »in vivo« du factor VIII ou du facteur IX après injection de différentes concentrés: application pratique. Nouv. Rev. Fr. d'Hémat. 1972; 12: 242.
7 Allain J. P., Krieger G. R. Prothrombin-complex concentrates in treatment of classical haemophilia with factor-VIII antibody. Lancet 1975; II: 1203.
8 Amphlett G. W., Byrne R., Castel-lino F. J. The binding of metal ions to bovine factor IX. J. Biol. Chem. 1978; 253: 6774.
9 Aronson D. L. Factor IX complex. Sem. Thromb. Haemost. 1979; 6: 28.
10 Aurousseau M. H., de Angelí J. L., Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis 1981; 10: 104.
11 Bajaj S. B., Rapaport S. I., Brown S. F. Isolation and characterization of human factor VII. Activation of factor VII by Xa. J. Biol. Chem. 1981; 256: 253.
12 Barrowcliffe T. W., Stableforth P., Dormandy K. M. Small scale preparation and clinical use of factor IX-prothrombin complex. Vox Sang 1973; 25: 426.
13 Barton P. G., Jackson C. M., Hana-han D. J. Relationship between factor V and activated factor X in the generation of prothrombinase. Nature 1967; 214: 923.
14 Bick R. L., Schmalhorst W. R., Fekete L. Disseminated intravascular coagulation and blood component therapy. Transfusion 1976; 16: 361.
15 Bick R. L., Schmalhorst W. R., Shan-brom E. Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Digest. Dis. 1975; 20: 741.
16 Bidwell E., Booth J. M., Dike G. W. R., Denson K. W. E. The preparation for therapeutic use of a concentrate of factor IX containing also factors II. VII and X. Brit. J. Haematol. 1967; 13: 568.
17 Bidwell E., Rizza C. R., Dike G. W. R., Snape T. J. Clinical use of factor IX concentrates. Thromb. Haemost. 1976; 35: 488.
18 Biggs R., Bidwell E., Handley D. A., Macfarlane R. G., Trueta J., Elliot-Smith A., Dike G. W. R., Ash B. J. The preparation and assay of a Christmas-factor (factor IX) concentrate and its use in the treatment of two patients. Brit. J. Haemat. 1961; 7: 349.
19 Biggs R., Denson K. W. E. The fate of prothrombin and factors VII IX, and X transfused to patients deficient in these factors. Brit. J. Haemat. 1963; 9: 532.
20 Biggs R., Douglas A. S., Macfarlane R. G., Dacie J. V., Pitney W. R., Mers-key C., O'Brien J. R. »Christmas disease« a condition previously mistaken for haemophilia. Brit. med. J. 1952; 2: 1378.
21 Blatrix C., Soulier J. P. Préparation d'une fraction riche en prothrombine procon-vertine, facteur Stuart et en facteur anti-hémophilic B (fraction P.P.B.). Pathol. Biol. 1959; 7: 2477.
22 Blatt P. M., Lundblad R. L., King-don H. S., McLean G., Roberts H. R. Throm-bogenic material in prothrombin complex concentrates. Ann. Intern. Med. 1974; 81: 766.
23 Breen F. A., Tullís J. L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. J. Amer. Med. Ass. 1969; 208: 1848.
24 Buchanan G. R., Kevy S. V. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatr. 1978; 62: 767.
25 Bucher D., Nebelin E., Thomsen J., Stenflo J. Identification of γ-carboxy-glutamic acid residues in bovine factor IX and X and in a new vitamin K-dependent protein. FEBS Lett. 1976; 68: 239.
26 Campbell E. W., Neff S., Bowdler A. J. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena. Transfusion 1978; 18: 94.
27 Cartmile T. B., Castaldi P. A., Halliday E. J. Cardiac-valve surgery in factor-VII deficiency. Lancet I 1968; 752.
28 Cash J. D., Owens R., Dalton R. G., Prescott R. J. Thrombogenicity of factor IX concentrates: in vitro and in vivo (rabbit) studies. Vox Sang 1978; 35: 105.
29 Cederbaum A. I., Blatt P. M., Roberts H. R. Intravascular coagulation with use of human prothrombin complex concentrates. Ann. Intern. Med. 1976; 84: 683.
30 Chandra S., Wickerhauser M. Contact factors are responsible for the thrombogenicity of prothrombin complex. Thromb. Res. 1979; 14: 189.
31 Coan M. H., Fournel M. A., Mozen M. M. Properties of commercial factor IX concentrates. Ann. N.Y. Acad. Sci. 1981; 370: 731.
32 Cohen O. Diskussion von Haanen C, McShine R. L., Kunst A. Preparation and clinical use of factor IX concentrate PPSB according to Soulier. Vox Sang 1969; 16: 408.
33 Collen D., Semeraro N., Tricot J. P., Vermylen J. Turnover of fibrinogen. plasminogen and prothrombin during exercise in man. J. Appl. Physiol. 1977; 42: 865.
34 Comp P.C., Esmon C. T. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J. Clin. Invest. 1981; 68: 1221.
35 Davey R. J., Shashaty G. G., Rath C. E. Acute coagulopathy following infusion of prothrombin complex concentrate. Amer. J. Med. 1976; 60: 719.
36 Davie E. W., Fujikawa K., Kurachi K., Kiesel W. The role of serine proteases in blood coagulation cascade. In Meister A. (Ed.): Advances in enzymology and related areas of molecular biology. John Wiley & Sons; New York.: 48 277 1979
37 Delange C, Lagacé R. Hépatite associée à la prise de Konyne: Observation clinico-pathologique de 10 cas. Union Med. Can. 1974; 103: 1207.
38 DeWitt R. T., Feinstein D. I. Prothrombin complex concentrate. Use in a hemophiliac with a factor VIII inhibitor. Arch. Intern. Med. 1977; 137: 1211.
39 Didisheim P., Loeb J., Blatrix Ch., Soulier J.-P. Preparation of a human plasma fraction rich in prothrombin proconvertin, Stuart factor and PTC and a study of its activity and toxicity in rabbits and in man. J. Lab. Clin. Med. 1959; 53: 322.
40 van Dieijen G., Tans G., Rosing J., Hemker H. C. The role of phospholipid and factor Villa in the activation of bovine factor X. J. Biol. Chem. 1981; 256: 3433.
41 Dike G. W. R., Bidwell E., Rizza C. R. The preparation and clinical use of a new concentrate containing factor IX pro-thrombin and factor X and of a separate concentrate containing factor VII. Brit. J. Haematol. 1972; 22: 469.
42 Dike G. W. R., Griffiths D., Bidwell E., Snape T. J., Rizza C. R. A factor VII concentrate for therapeutic use. Brit. J. Haematol. 1980; 45: 107.
43 Dioguardi N., Mannucci P. M. Prothrom-bin-complex concentrate in liver disease. Lancet II 1975; 188.
44 Dowing M. R., Butkowski R. J., Clark M. M., Mann K. G. Human prothrombin activation. J. Biol. Chem. 1975; 250: 8897.
45 Edell S. Anaphylaxis after Konyne. New Engl. J. Med. 1971; 285: 580.
46 Edson J. R. Prothrombin-complex concentrates and thrombosis. New Engl. J. Med. 1974; 290: 403.
47 Eggeling B., Lechler E., Asbeck F. Untersuchungen kommerzieller Präparationen des Prothrombinkomplexes (PPSB) auf aktivierte Faktoren. Verh. Dtsch. Ges. inn. Med. 1975; 81: 1140.
48 Ekert H., Price D. A., Lane J. L., Dean F. L. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII. Aust. N. Z. Med. 1979; 9: 241.
49 Elödi E., Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb. Res. 1978; 12: 797.
50 Esmon C. T., Jackson C. M. The conversion of prothrombin to thrombin. III. The factor Xa catalized activation of prothrombin. J. Biol. Chem. 1974; 249: 7782.
51 Esmon C. T., Stenflo J., Suttie J. W. A new vitamin K-dependent protein. J. Biol. Chem. 1976; 251: 3052.
52 Esnouf M. P. Current perspectives of factor X. Bibl. haemat. 1978; 44: 75.
53 Faria R., Fiumara N. J. Hepatitis B associated with Konyne. New Engl. J. Med. 1972; 287: 358.
54 Thromboembolic complication of factor IX complex. FDA Drug Bull. 10 1980: 25
55 Fischer M., Falkensammer C., Gauss P., Korp W., Kubiena K., Neubert J., Schnack H., Weissmann A. Anwendung eines neuen Prothrombinkomplex-Kon-zentrates bei Patienten unter Antikoagu-lantientherapie und Patienten mit Lebererkrankungen. Med. Welt 1973; 24: 1899.
56 Frick P. G., Riedler G., Brögli H. Dose response and minimal daily requirement for vitamin K in man. J. Appl. Physiol. 1967; 23: 387.
57 Fuehrt J. H., Mahrer P. Myocardial infarction after factor IX therapy. J. Amer. Med. Ass. 1981; 245: 1455.
58 Gazzard B. G., Henderson J. M., Williams R. The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 1975; 16: 621.
59 Gazzard B. G., Lewis M. L., Ash G., Rizza C. R., Bidwell E., Williams R. Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Gut 1974; 15: 993.
60 Gilchrist G. S., Ekert H., Shanbrom E., Hammond D. Evaluation of a new concentrate for the treatment of factor IX deficiency. New Engl. J. Med. 1969; 280: 291.
61 Göbel U., Petrich C. Zur Therapie der Blutungsneigung bei Vitamin-K-Mangel oder Leberfunktionsstörung im Säuglingsalter. Mschr. Kinderheilk. 1974; 122: 60.
62 Graham J. B. Stuart clotting defect and Stuart factor. Thromb. Diathes. haemorrh. Suppl. ad 1960; 4: 22.
63 Grammens G. L., Breckenridge R. T. Complications with Christmas factor (factor IX) concentrates. Ann. Intern. Med. 1974; 80: 666.
64 Green G., Poller L., Dymock I. W., Thomsen J. M. Use of factor-VII-rich prothrombin complex concentrate in liver disease. Lancet I 1975; 1311.
65 Griffin J. H., Evat B., Zimmerman T. S., Kleiss A. C., Wideman C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 1981; 68: 1370.
66 Guillin M.C., Ménaché D., Barge J., Rueff B., Fauvert R. Les troubles de l'hémostase au cours des hépatites virales graves: Etudes clinique anatomique et histologique. Ann. Med. Interne (Paris) 1971; 122: 605.
67 Gunay U., Choi H. S., Maurer H. S., Hruby M., Honig G. R. Commercial preparations of prothrombin complex. Amer. J. Dis. Child. 1973; 126: 775.
68 Haanen C., McShine R. L., Kunst A. Preparation and clinical use of factor IX concentrate PPSB according to Soulier. Vox Sang 1969; 16: 398.
69 Hellerstein L. J., Deykin D. Hepatitis after Konyne administration. New Engl. J. Med. 1971; 284: 1039.
70 Hemker H.C., Esnouf M. P., Hemker P. W., Swart A. C. W., Macfar-lane R. G. Kinetics of the formation of prothrombin converting activity in a purified system. Nature 1967; 215: 248.
71 Hemker H.C., Kahn M. J. P. Reaction sequence of blood coagulation. Nature 1967; 215: 1201.
72 Heystek J., Brummelhuis H. G. J., Krijnen H. W. Contributions to the optimal use of human blood. Vox Sang 1973; 25: 113.
73 Hoag M. S., Johnson F. F., Robinson J. A., Aggeler P. M. Treatment of hemophilia B with a new clotting-factor concentrate. New Engl. J. Med. 1969; 280: 581.
74 Hoofnagle J. H., Aronson D., Roberts H. Serologic evidence for hepatitis B virus infection in patients with hemophilia B. Thromb. Diathes. haemorrh. 1975; 33: 606.
75 Hoppe I. Hepatitis auslösende Faktoren bei kardiochirurgischen Eingriffen. In Frösner G, Lasch H.-G., Lechler E. (Hrsg.): Plasmaproteine und Virushepatitis 33 Springer; Berlin, Heidelberg, New York: 1982
76 Hougie C, Denson K. W. E., Bigs R. A study of the reaction product of factor VIII and factor IX by gel filtration. Thrombos. Diathes. haemorrh. 18: 211 1967;
77 Huitín M. B. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028.
78 Hultin M. B., Nemerson ć. Activation of factor X by factor IX a and VIII; a specific assay for factor IX a in the presence of thrombin-activated factor VIII. Blood 1978; 52: 928.
79 Jackson C. M., Suttie J. W. Recent developments in understanding the mechanism of vitamin K and vitamin K antagonist drug action and the consequence of vitamin K action in blood coagulation. Progr. Hematol. 1977; 10: 233.
80 Jesty J. The inhibition of activated bovine coagulation factors X and VII by anti-thrombin III. Arch. Biochem. Biophys. 1978; 185: 165.
81 Kalousek F., Konigsberg W., Nemerson Y. Activation of factor IX by activated factor X: a linkage between the extrinsic and intrinsic coagulation systems. FEBS Lett. 1975; 50: 382.
82 Kasper C. K. Postoperative thrombosis in hemophilia B. New Engl. J. Med. 1973; 289: 160.
83 Kasper C. K. Blood - Its derivatives and its problems - factor IX. Ann. N. ć. Acad. Sci. 1975; 240: 172.
84 Kasper C. K. Thromboembolic complications. Thrombos. Diathes. haemorrh. 1975; 33: 640.
85 Kelly P., Penner J. A. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. J. Amer. Med. Ass. 1976; 236: 2061.
86 Kingdon H. S. Evolution of enzyme activities and fibrin formation after contact of plasma with glass. J. Biomed. Mater. Res. 1969; 3: 25.
87 Kingdon H. S., Lundblad R. L., Veltkamp J. J., Aronson D. L. Potentially thrombogenic material in factor IX concentrates. Thrombos. Diathes. haemorrh. 1975; 33: 617.
88 Kurczynski E. M., APenner J. Activated prothrombin complex for patients with factor VIII inhibitors. New Engl. J. Med. 1974; 291: 164.
89 Lane J. L., Rizza C. R., Snape T. J. A five-year experience of the use of factor IX type DE(1) concentrate for the treatment of Christmas disease at Oxford. Brit. J. Haematol. 1975; 30: 435.
90 Lechler E. Das Problem der Throm-bogenität bei der Substitutionstherapie mit Konzentraten vom PPSB-Typ. Forschg. erg. Transf. med. Immunhämatol. 1978; 4: 89.
91 Lechler E., Eggeling B. Die potentiell thrombogene Wirkung von Prothrombin-Komplex-Präparaten und ihre Wirkung bei der Hemmkörperhämophilie. In Schumacher K, Grosser K.-D. (Hrsg.) Aktuelle Probleme der inneren Medizin. S.283. Schattauer; Stuttgart: 1977
92 Lechler E., Nenci G. G. Gelfiltration der Faktoren IX und X: Änderung des Filtrationsverhaltens nach Aktivierung. In Lüscher E. F. (Hrsg.) Die Rolle der Blutplättchen bei der Thrombose. Das Problem der Hyperkoagulabilität, S. 193. Schattauer; Stuttgart, New York: 1976
93 Lechner K. Coagulation abnormalities in liver disease. Sem. Thromb. Hemost. 1977; 4: 40.
94 Loeliger E. A., Hensen A., Matern M. J., Veitkamp J. J., Bruning P. F., Hemker H. C. Treatment of haemophilia B with purified factor IX (PPSB). Folia Med. Neerl. 1967; 10: 112.
95 Lowe G. D. O., Harvie A., Forbes C. D., Prentice C. R. M. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. Brit. med. J. 1976; 2: 1110.
96 Ludwig E., Lechner K. Prophylaktische Behandlung bei schwerer Hämophilie B mit einem Faktor-IX-Konzentrat. Dtsch. med. Wschr. 1974; 99: 1355.
97 Lusher J. M., Shapiro S. S., Palascak J. P., Vijaya Rao A., Levine P. H., Blatt P. M. The hemophilia study group: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New Engl. J. Med. 1980; 303: 421.
98 Machin S. J., Miller B. R. Thrombosis and factor IX concentrates. Lancet 1978; 1: 1367.
99 Magnusson S., Sottrup-Jensen L., Petersen T. E., Morris H. R., Dell A. Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett. 1974; 44: 189.
100 Mannucci P. M., Franchi F., Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet II 1976; 542.
101 Marchesi S. L., Burney L. Letter. New Engl. J. Med. 1974; 290: 403.
102 Marassi A., Manzullo V., diCarto V., Mannucci P. M. Thromboembolism following prothombin complex concentrates and major surgery in severe liver disease. Thromb. Haemost. 1978; 39: 787.
103 Mariani G., Mannucci P. M., Maz-zucomi M. G., Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb. Haemost. 1978; 39: 675.
104 Marlar R. A., Griffin J. H. Deficiency of protein C inhibitor in combined factor V/ VIII deficiency disease. J. Clin. Invest. 1980; 66: 1186.
105 Marlar R. A., Griffin J. H. Alternative pathways of thromboplastin-dependent activation of human factor X in plasma. Ann. N.Y. Acad. Sci. 1981; 370: 325.
106 Marlar R. A., Kleiss A. J., Griffin J. H. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann. N.Y. Acad. Sci. 1981; 370: 303.
107 Ménaché D., Fauvert R., Soulier J.-P. Utilisation en hépatologie d'une fraction contenant la prothrombine le complex proconvertine-facteur Stuart et le facteur anti-hémiphilique B (P.P.B.). Path. Biol. 1959; 7: 2515.
108 Middleton S. M., Bennett I. H., Smith J. K. A therapeutic concentrate of coagulation factors II IX and X from citrated, factor VIII-depleted plasma. Vox Sang 1973; 24: 441.
109 Miura Y., Abe T., Kazama M., Yasuda J. A test method for the absence of throm-bogenicity in factor IX complex. Develop. biol. Stand. 1979; 44: 189.
110 O'Connor M. L., Meck E. S., Simmons A. Detection of HBsAg in coagulation factor IX concentrates. Transfusion 1977; 17: 44.
111 O'Leary D., Ruymann F. B., Conrad M. Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting factor concentrate (Konyne). J. Lab. Clin. Med. 1971; 77: 23.
112 O'Reilly R. A. Anticoagulant antithrombotic and thrombolytic drugs. In: Good-man-Gilman A., Goodman L. S., Gil-man A. (Eds.): The pharmacological basis of therapeutics 1347 6th edition MacMil-lan Publishing Co.INC; New York: 1980
113 Osterud B., Bouma B. N., Griffin J. H. Human blood coagulation factor IX. J. Biol. Chem. 1978; 253: 5946.
114 Osterud B., Miller-Andersson M., Abildgaard U., Prydz H. The effect of anti-thrombin III on the activity of the coagulation factors VII. IX and X. Thromb. Haemost. 1976; 35: 295.
115 Østerud B., Rapaport S. I. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. 1977; 74: 5260.
116 Østerud B., Schiffman S. Gel filtration of factors II, VII, IX, IXa and X. Thromb. Diathes. haemorrh. 1972; 28: 317.
117 Penner J. A. Prothrombin complex concentrates. Bibl. haemat. 1978; 44: 81.
118 Penner J. A., Abildgaard C. F. Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX. New Engl. J. Med. 1979; 300: 565.
119 Preston F. E., Malia R. G., Lilley-man J. S., Blackburn E. K. Heparinized clotting factor concentrates in patients with Christmas disease and liver disease. Thromb. Haemost. 1977; 38: 504.
120 Preston F. E., Winfield D. A., Malia R. G., Blackburn E. K. Serial changes in the coagulation system following clotting factor concentrate infusion. Thromb. Diathes. haemorrh. 1975; 34: 475.
121 Prowse C. V., Cash J. D. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the south-east of Scotland. Brit. J. Haematol. 1981; 47: 91.
122 Radcliffe R., Nemerson Y. Mechanism of activation of bovine factor VII. J. Biol. Chem. 1976; 251: 4797.
123 Rizza C. R., Spooner R. J. D. Home treatment of haemophilia and Christmas disease: five year's experience. Brit. J. Haematol. 1977; 37: 53.
124 Roberts H. R., Lechler E., Webster W. P., Penick G. D. Survival of transfused factor X in patients with Stuart disease. Thromb. Diathes. haemorrh. 1965; 13: 305.
125 Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 1973; 248: 6490.
126 Rosenberg J. D., McKenna P. W., Rosenberg R. D. Inhibition of human factor IXa by human antithrombin. J. Biol. Chem. 1975; 250: 8883.
127 Rossiter S. J., Miller D. C., Raney A. A., Oyer P. E., Reitz B. A., Stinson E. B., Shumway N. E. Hepatitis risk in cardiac surgery patients receiving factor IX concentrates. J. Thorac. Cardiovasc. Surg. 1979; 78: 203.
128 Sandler S. G., Rath C. E., Ruder A. Prothrombin complex concentrates in acquired hypoprothrombinemia. Ann. Intern. Med. 1973; 79: 485.
129 Schimpf K., Baumann P. Die ambulante Dauerbehandlung der Hämophilie B. Dtsch. med. Wschr. 1976; 101: 233.
130 Schimpf K., Zimmermann K., Kömpf B. DIC and postoperative wound bleeding under factor IX substitution therapy in a case of haemophilia B successful treatment with heparin. Thromb. Res. 1976; 8: 65.
131 Di Scipio R. G., Hermodson M. A., Yates S. G., Davie E. W. A comparison of human prothrombin factor IX (Christmas factor), factor X (Stuart factor), and protein. S. Biochem. 1977; 16: 698.
132 Scipio Di, Kurachi K., Davie E. W. Activation of human factor IX (Christmas factor). J. Clin. Invest 1978; 61: 1528.
133 Seeler R. A., Telischi M., Lengehen-nig P. L., Ashenhurst J. B. Comparison of anti-A and anti-B titers in factor VIII and IX concentrates. J. Pediatr. 1976; 89: 87.
134 Seligsohn U., Kasper C. K., Osterud B., Rapaport S. I. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828.
135 Shah D. V., Suttie J. W. The vitamin K-dependent in vitro production of prothrombin. Biochem. Biophys. Res. Comm. 1974; 60: 1397.
136 Smith J. K., Bidwell E. Therapeutic material used in the treatment of coagulation defects. Clin. Haematol. 1979; 8: 183.
137 Soulier J. P., Blatrix C., Steinbuch M. Fractions »coagulantes« contenant les facteurs de coagulation adsorbables par le phosphate tricalcique. Presse méd. 1964; 72: 1223.
138 Soulier J. P., Josso F., Steinbuch A Cosson M. The therapeutic use of fraction P. P.S.B. Bibl. haemat. 1968; 29: 1127.
139 Soulier J.-P., Prou-Wartelle O., Josso F. Demi-vie de la prothrombine vraie (fac teur II). Nouv. Rev. Fr. Hématol. 1962; 2: 673.
140 Soulier J. P., Prou-Wartelle O., Josso F. Demi-vie de la prothrombine vraie (facteur II). Bibl. haemat. 1964; 19: 156.
141 Steinberg M. H., Dreiling B. J. Vascular lesions in hemophilia B. New Engl. J. Med. 1974; 289: 592.
142 Stenflo J. A new vitamin K-dependent protein. J. Biol. Chem. 1976; 251: 355.
143 Stenflo J., Fernlund P., Egan W. Vitamin K dependent modification of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA 1974; 71: 2730.
144 Stenflo J., Suttie J. W. Vitamin K-dependent formation of gamma-carboxyglutamic acid. Ann. Rev. Biochem. 1977; 46: 157.
145 Strauss H. S. Surgery in patients with congenital factor VII deficiency (congenital hypoproconvertinemia). Blood 1965; 25: 325.
146 Suomela H., Myllyä G., Raaska E. Preparation and properties of a therapeutic factor IX concentrate. Vox Sang 1977; 33: 37.
147 Suttie J. W., Hageman J. M., Lehr-man S. R., Rich D. H. Vitamin K-dependent carboxylase. Development of a peptide substrate. J. Biol. Chem. 1976; 251: 5837.
148 Suttie J. W., Jackson C. M. Prothrombin structure activation and biosynthesis. Physiol. Rev. 1977; 57: 1.
149 Taberner D. A., Thomsen J. M., Poller L. Comparison of prothrombin complex concentrates and Vitamin K₁ in oral anticoagulant reversal. Brit. med. J. 1976; 2: 83.
150 Tilsner V., Greul W. Behandlung von Blutungskomplikationen unter Antikoa-gulantientherapie mit Cumarinen. Med. Welt 1975; 26: 2332.
151 Trobisch H., Schmitz L., Richter O. Identifizierung proteolytischer Enzyme in Pro-thrombinkonze'ntraten. In Schimpf, K. (Hrsg.): Fibrinogen, Fibrin und Fibrinkleber. Nebenwirkungen der Therapie mit Gerinnungsfaktorenkonzentraten, S. 348. Schattauer, Stuttgart; New York: 1980
152 Tullis J. L., Merlin M., Jurigian P. Clinical use of human prothrombin complexes. New Engl. J. Med. 1965; 273: 667.
153 Varadi K., Hemker H. C. Kinetics of the formation of the factor X activating enzyme of the blood coagulation system. Thromb. Res. 1976; 8: 303.
154 Waltl H, Kurz R., Mitterstieler G., Födisch H. J., Hohenauer L., Rössler H. Intracranial haemorrhage in low-birth-weight infants and prophylactic administration of coagulation-factor concentrate. Lancet I 1973: 1248
155 Weinreb N. L., Minsky N. Serious reaction after Konyne. New Engl. J. Med. 1971; 285: 1151.
156 White G. C., Lundblad R. L., Kingdon H. S. Prothrombin complex concentrates: preparation properties, and clinical use. Curr. Top. Hematol. 1979; 2: 203.
157 White G.C., Roberts H. R., Kingdon H. S., Lundblad R. L. Prothrombin complex concentrates: potentially throm-bogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159.
158 Wyke R. J., Thornton A., Portmann B., Zuckerman A. J., Tsiquaye K. N., White Y., Das P. K., Williams R. Transmission of non-A non-B Hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet I 1979; 520.
159 Yin E. T., Wessler S., Stoll P. J. Identity of plasma activated factor X inhibitor with antithrombin III and heparin cofactor. J. Biol. Chem. 1971; 246: 3712.
160 Yorke A. J. Factor VII deficiency and surgery. Is preoperative replacement necessary?. J. Amer. Med. Ass. 1977; 238: 424.
161 Zauber N. P., Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine (Baltimore) 1977; 56: 213.